Pharmacokinetics and Toxicity Prediction of Lansium domesticum Corr.

  • Gusti Rizaldi Bachelor of Pharmacy Study Program, Faculty of Pharmacy, Borneo Lestari University
  • Norhayati Bachelor of Pharmacy Study Program, Faculty of Pharmacy, Borneo Lestari University
DOI: https://doi.org/10.24123/mpi.v6i1.6416
Abstract Views: 24 times
PDF Downloads: 17 times
Keywords: ADMET, knapsack, Lansium domesticum, pkcsm, swissadme

Abstract

A wide range of compounds has been isolated from Lansium domesticum Corr. Secondary metabolites are commonly utilised as valuable resources for potential drug for research and development. An exemplary drug candidate must possess efficacy against the therapeutic target, safety, and favourable pharmacokinetic characteristics. The objective of this study was to determine the pharmacokinetic characteristics and toxicity potentials of 23 compounds derived from Lansium domesticum Corr. utilising the pKCSM online tool and the drug-likeness using swissADME online tool. Based on pKCSM prediction, compounds 14 (methyl angolensate) and 22 (7,14(27)-Onoceradiene-3,21-dione) from Lansium domesticum Corr. are identified as having favourable pharmacokinetic properties and are not expected to exhibit mutagenic or hepatotoxic effects. The LD50 values for compounds 14 and 22 were 2.983 and 1.813 (mol/kg), respectively, indicating their lethal dosages. In conclusion, only compound 14 that also met all the Lipinski’s Rule of Five.

Downloads

Download data is not yet available.
Published
2024-06-26
How to Cite
Rizaldi, G., & Norhayati. (2024). Pharmacokinetics and Toxicity Prediction of Lansium domesticum Corr. MPI (Media Pharmaceutica Indonesiana), 6(1), 21-29. https://doi.org/10.24123/mpi.v6i1.6416
Issue
Vol. 6 No. 1 (2024): JUNE
Section
Original Research Articles
Copyright (c) 2024 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Creative Commons License

Articles published in MPI are licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA) license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and MPI, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.

Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to MPI to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.

By publishing in MPI, authors grant any third party the right to use their article to the extent provided by the CC BY-SA license.